Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea
Sponsor: Bayer
Listed as NCT01555463, this PHASE3 trial focuses on Papulopustular Rosacea and remains completed. Sponsored by Bayer, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- LEO Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anderson, United States , Austin, United States , Birmingham, United States , Boynton Beach, United States , Buffalo Grove, United States , Chapel Hill, United States , Chicago, United States , Colorado Springs, United States , East Windsor, United States , Fremont, United States and 34 more locations